{"id":57495,"date":"2024-02-27T17:47:19","date_gmt":"2024-02-27T17:47:19","guid":{"rendered":"https:\/\/medsname.com\/hcqs\/"},"modified":"2026-04-30T10:24:26","modified_gmt":"2026-04-30T10:24:26","slug":"hcqs","status":"publish","type":"product","link":"https:\/\/medsbase.com\/bg\/product\/hcqs\/","title":{"rendered":"HCQS"},"content":{"rendered":"

<\/p>\n

\n

\u0411\u044a\u0440\u0437 \u043e\u0442\u0433\u043e\u0432\u043e\u0440<\/h3>\n

HCQS<\/strong> \u0441\u044a\u0434\u044a\u0440\u0436\u0430 hydroxychloroquine sulfate<\/strong> 200 mg and 400 mg (Cipla). It treats and prevents \u043c\u0430\u043b\u0430\u0440\u0438\u044f, \u0447\u0443\u0432\u0441\u0442\u0432\u0438\u0442\u0435\u043b\u043d\u0430 \u043a\u044a\u043c \u0445\u043b\u043e\u0440\u043e\u0445\u0438\u043d<\/strong>, and is the first-line aminoquinoline for rheumatoid arthritis<\/strong>, systemic lupus erythematosus<\/strong>, discoid lupus<\/strong>, \u0438 Sj\u00f6gren’s syndrome<\/strong>. Dose: 400 mg\/day for autoimmune disease (long-term maintenance \u2264 5 mg\/kg\/day actual body weight); 800 mg loading then 400 mg at 6 \/ 24 \/ 48 h for acute uncomplicated chloroquine-sensitive malaria. Mandatory baseline + annual ophthalmology screening<\/strong> after 5 years of continuous use to detect retinopathy. Modern endemic areas (sub-Saharan Africa, India, Southeast Asia, Amazon) have widespread chloroquine resistance \u2014 hydroxychloroquine is NOT the right prophylaxis for those destinations. Take with food to reduce GI upset.<\/p>\n<\/div>\n

\ud83c\udfed \u041f\u0440\u043e\u0438\u0437\u0432\u0435\u0434\u0435\u043d\u043e \u043e\u0442 WHO-GMP \u0441\u0435\u0440\u0442\u0438\u0444\u0438\u0446\u0438\u0440\u0430\u043d \u043f\u0440\u043e\u0438\u0437\u0432\u043e\u0434\u0438\u0442\u0435\u043b<\/strong>  \u00b7  \ud83d\udce6 \u0414\u0438\u0441\u043a\u0440\u0435\u0442\u043d\u0430 \u043e\u043f\u0430\u043a\u043e\u0432\u043a\u0430<\/strong>  \u00b7  \ud83c\udf0d \u0414\u043e\u0441\u0442\u0430\u0432\u043a\u0430 \u043f\u043e \u0446\u0435\u043b\u0438\u044f \u0441\u0432\u044f\u0442<\/strong>  \u00b7  \u2b50 1,400+ \u043f\u043e\u0442\u0440\u0435\u0431\u0438\u0442\u0435\u043b\u0441\u043a\u0438 \u0440\u0435\u0432\u044e\u0442\u0430<\/a><\/strong><\/div>\n

\ud83d\udee1\ufe0f \u0412\u0441\u044f\u043a\u0430 \u043f\u043e\u0440\u044a\u0447\u043a\u0430 \u0435 \u043f\u043e\u043a\u0440\u0438\u0442\u0430 \u043e\u0442 \u043d\u0430\u0448\u0430\u0442\u0430 \u041f\u043e\u043b\u0438\u0442\u0438\u043a\u0430 \u0437\u0430 \u043f\u043e\u0432\u0442\u043e\u0440\u043d\u0430 \u0438\u0437\u043f\u0440\u0430\u0442\u043a\u0430<\/strong><\/a> \u2014 if your parcel does not arrive within 20 business days we ship a free replacement on EMS or ITPS courier.<\/p>\n

\u0417\u0430\u0449\u043e \u0434\u0430 \u043f\u043e\u0440\u044a\u0447\u0432\u0430\u0442\u0435 \u043e\u0442 MedsBase<\/h3>\n

HCQS is sourced from a WHO-GMP certified manufacturer and shipped worldwide in discreet packaging. Every order is backed by our \u041f\u043e\u043b\u0438\u0442\u0438\u043a\u0430 \u0437\u0430 \u043f\u043e\u0432\u0442\u043e\u0440\u043d\u0430 \u0438\u0437\u043f\u0440\u0430\u0442\u043a\u0430<\/a> \u0438 \u043f\u043e\u0434\u0434\u044a\u0440\u0436\u0430\u043d\u0430 \u043e\u0442 \u043d\u0430\u0448\u0438\u0442\u0435 1,400+ \u043f\u043e\u0442\u0440\u0435\u0431\u0438\u0442\u0435\u043b\u0441\u043a\u0438 \u0440\u0435\u0432\u044e\u0442\u0430<\/a>. \u0421\u0432\u0435\u0442\u043e\u0432\u043d\u0430 \u0434\u043e\u0441\u0442\u0430\u0432\u043a\u0430 \u0431\u0435\u0437 \u0438\u0437\u0438\u0441\u043a\u0432\u0430\u043d\u0435 \u0437\u0430 \u0440\u0435\u0446\u0435\u043f\u0442\u0430.<\/p>\n

About HCQS<\/h2>\n

HCQS is a multi-strength hydroxychloroquine sulfate tablet manufactured by Cipla under WHO-GMP certified conditions. Hydroxychloroquine is a 4-aminoquinoline antimalarial that doubles as the workhorse conventional synthetic disease-modifying anti-rheumatic drug (csDMARD)<\/strong> for mild-to-moderate rheumatoid arthritis and connective-tissue disease, with the lowest toxicity profile of any DMARD when dosed correctly.<\/p>\n

How hydroxychloroquine works<\/h2>\n

Hydroxychloroquine accumulates in the acidic lysosomes of cells. In malaria parasites<\/strong> it interferes with haemoglobin digestion in the food vacuole, allowing toxic free haem to accumulate and kill the parasite. In autoimmune disease<\/strong> the lysosomotropic effect raises lysosomal pH, which interferes with antigen processing by dendritic cells, dampens Toll-like receptor signalling (especially TLR-7 and TLR-9 which recognise self-nucleic acids), and reduces interferon-\u03b1 production. The dual mechanism explains why a single drug treats two unrelated diseases.<\/p>\n

Half-life is ~ 40 days (steady state 4\u20136 weeks). Effect on autoimmune disease takes 8\u201312 weeks to develop and continues to deepen over 6 months \u2014 patience and adherence matter.<\/p>\n

\u041f\u043e\u043a\u0430\u0437\u0430\u043d\u0438\u044f \u0438 \u0434\u043e\u0437\u0438\u0440\u0430\u043d\u0435<\/h2>\n
\n\n\n\n\n\n\n\n\n\n\n
\u041f\u043e\u043a\u0430\u0437\u0430\u043d\u0438\u0435<\/th>\n\u0414\u043e\u0437\u0430<\/th>\n\u041f\u0440\u043e\u0434\u044a\u043b\u0436\u0438\u0442\u0435\u043b\u043d\u043e\u0441\u0442 \/ \u0431\u0435\u043b\u0435\u0436\u043a\u0438<\/th>\n<\/tr>\n<\/thead>\n
Rheumatoid arthritis (mild\u2013moderate)<\/td>\n200\u2013400 mg\/day in 1\u20132 divided doses (max 5 mg\/kg\/day actual body weight)<\/td>\nOnset 8\u201312 weeks. Long-term maintenance. Often combined with methotrexate or sulfasalazine.<\/td>\n<\/tr>\n
\u0421\u0438\u0441\u0442\u0435\u043c\u0435\u043d \u043b\u0443\u043f\u0443\u0441 \u0435\u0440\u0438\u0442\u0435\u043c\u0430\u0442\u043e\u0437\u0443\u0441 (SLE)<\/td>\n200\u2013400 mg\/day, max 5 mg\/kg\/day<\/td>\nBackground therapy for almost all SLE patients per EULAR \u2014 reduces flares, organ damage, thrombosis, and improves survival.<\/td>\n<\/tr>\n
Discoid \/ cutaneous lupus<\/td>\n200\u2013400 mg\/\u0434\u0435\u043d<\/td>\nFirst-line systemic for skin-only lupus. Can take 8\u201312 weeks for visible improvement.<\/td>\n<\/tr>\n
Sj\u00f6gren’s syndrome<\/td>\n200\u2013400 mg\/\u0434\u0435\u043d<\/td>\nModest-evidence improvement in fatigue + arthralgia; little effect on dryness.<\/td>\n<\/tr>\n
Acute uncomplicated chloroquine-sensitive P. falciparum \/ P. vivax \/ P. ovale \/ P. malariae<\/td>\n800 mg loading \u2192 400 mg at 6 h \u2192 400 mg at 24 h \u2192 400 mg at 48 h (total 2 g over 48 h)<\/td>\nTreatment course only \u2014 for chloroquine-sensitive areas. Add primaquine for radical cure of vivax\/ovale.<\/td>\n<\/tr>\n
Chloroquine-sensitive malaria prophylaxis<\/td>\n400 mg once weekly<\/td>\nStart 1\u20132 weeks before travel, continue weekly during exposure, continue 4 weeks after return. Limited modern utility \u2014 most destinations are resistant.<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<\/div>\n
\u041f\u0440\u0435\u0434\u0443\u043f\u0440\u0435\u0436\u0434\u0435\u043d\u0438\u0435 \u0437\u0430 \u0440\u0435\u0442\u0438\u043d\u043d\u0430 \u0442\u043e\u043a\u0441\u0438\u0447\u043d\u043e\u0441\u0442.<\/strong> Hydroxychloroquine accumulates in retinal pigment epithelium. Risk of irreversible bull’s-eye maculopathy<\/strong> rises sharply after 5 years of continuous use, especially at doses > 5 mg\/kg\/day actual body weight, with renal impairment, with concurrent tamoxifen, or in patients with pre-existing retinal disease. American Academy of Ophthalmology \/ Royal College of Ophthalmologists guidance: baseline fundus exam at start of long-term therapy + annual screening from year 5 onwards<\/strong> using spectral-domain OCT, automated visual field 10-2 (white test object), and fundus autofluorescence. Earlier screening if dose > 5 mg\/kg\/day, renal CrCl < 60 mL\/min, or concurrent tamoxifen. Stop the drug at the first sign of pre-toxicity \u2014 damage already established does not reverse.<\/div>\n
\u0411\u0435\u043b\u0435\u0436\u043a\u0430 \u0437\u0430 G6PD.<\/strong> Hydroxychloroquine has a much smaller G6PD-haemolysis signal than primaquine, but case reports exist in severe G6PD deficiency. If G6PD status is unknown, monitor for haemolysis (dark urine, pallor, fatigue) in the first weeks of high-dose therapy.<\/div>\n

\u0413\u0440\u0430\u0444\u0438\u043a \u0437\u0430 \u043d\u0430\u0431\u043b\u044e\u0434\u0435\u043d\u0438\u0435<\/h2>\n
\n\n\n\n\n\n\n\n\n\n
Time-point<\/th>\nInvestigation<\/th>\nReason<\/th>\n<\/tr>\n<\/thead>\n
\u0411\u0430\u0437\u043e\u0432\u043e \u0438\u0437\u0441\u043b\u0435\u0434\u0432\u0430\u043d\u0435<\/td>\nEye exam (fundus + OCT + visual field), FBC, U&E, LFTs, glucose, weight<\/td>\nEstablish retinal baseline + dose-by-actual-weight calculation + screen contraindications.<\/td>\n<\/tr>\n
Months 1\u20136<\/td>\nSymptom review at each clinical contact<\/td>\nGI tolerance, headache, mood, skin rash, muscle weakness.<\/td>\n<\/tr>\n
Year 1, then annually<\/td>\nFBC + LFTs<\/td>\nRare cytopenias and rare hepatotoxicity.<\/td>\n<\/tr>\n
Year 5, then annually<\/td>\nComprehensive ophthalmology screening (OCT + 10-2 visual field + fundus autofluorescence)<\/td>\nDetect early retinopathy before irreversible damage.<\/td>\n<\/tr>\n
Symptom-driven<\/td>\nCK + EMG if proximal weakness; nerve conduction if neuropathic symptoms<\/td>\nRare myopathy \/ neuromyopathy with long-term use.<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<\/div>\n

\u0421\u0442\u0440\u0430\u043d\u0438\u0447\u043d\u0438 \u0435\u0444\u0435\u043a\u0442\u0438<\/h2>\n